Recent commentary around Colgate-Palmolive (CL) centers on management’s 2030 plan, as investors weigh how premium product expansion and tighter digital plus in store integration might support the stock’s appeal after several years of organic sales growth.
See our latest analysis for Colgate-Palmolive.
Colgate-Palmolive’s recent 1-month share price return of 4.9% and year-to-date share price return of 19.4%, with the stock now at $92.76, suggest investors are increasingly pricing in the 2030 plan, while a 3-year total shareholder return of 29.54% points to steady, if measured, longer-term gains.
If you are weighing Colgate-Palmolive’s appeal alongside other consumer-focused ideas, it may be a good moment to broaden your watchlist with 20 top founder-led companies
With Colgate-Palmolive delivering six consecutive years of organic sales growth and trading only slightly below one set of analyst price targets, the key question is whether its 2030 plan still leaves upside or if the market already reflects that future growth.
Most Popular Narrative: 4.1% Undervalued
On the latest narrative view, Colgate-Palmolive’s fair value of $96.68 sits modestly above the $92.76 share price, framing a small valuation gap that hinges on how convincingly the 2030 plan translates into sales growth and margins over the next few years.
Expansion and premiumization of core oral care lines like Colgate Total, coupled with the roll-out of complementary products across 75 markets, are set to capture increased value from emerging middle-class consumers and rising health/hygiene awareness globally, supporting top-line organic sales acceleration and improved pricing power.
Curious what kind of revenue runway, margin lift, and future earnings multiple are baked into that fair value for Colgate-Palmolive? The full narrative spells out a detailed earnings bridge, built on steady top line expansion, a meaningfully higher profit margin, and a future valuation multiple that still sits above the broader household products group.
Result: Fair Value of $96.68 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, tighter consumer budgets and higher raw material costs could still pressure Colgate-Palmolive’s volumes and margins, which would challenge the assumptions behind that 4.1% undervaluation gap.
Find out about the key risks to this Colgate-Palmolive narrative.
Another View: Colgate-Palmolive Through Earnings Multiples
While the SWS model points to Colgate-Palmolive trading below an estimated future cash flow value of $125.13, the picture looks different when you look at the current P/E. At 35.5x versus a fair ratio of 24x, the stock carries a premium to both the US and global household products groups.
That kind of gap suggests limited room for disappointment if growth or margins fall short. The key question is whether you trust the cash flow story more than today’s earnings multiple.
See what the numbers say about this price — find out in our valuation breakdown.
Next Steps
If the mixed messages around Colgate-Palmolive’s valuation leave you on the fence, now is a good time to review the data for yourself and weigh the balance of concerns and potential upside before deciding how it fits your portfolio, starting with 3 key rewards and 3 important warning signs.
Looking for more investment ideas beyond Colgate-Palmolive?
Once you have formed a view on Colgate-Palmolive, you can keep your momentum going by scanning other opportunities that might refine your portfolio’s balance of risk, income, and growth.
- Target resilience by focusing on companies that pass strict balance sheet and fundamentals checks with the solid balance sheet and fundamentals stocks screener (47 results)
- Hunt for mispriced opportunities that combine quality and attractive valuations using the 41 high quality undervalued stocks
- Spot early stage companies with stronger financials than many peers before they hit the spotlight through the 21 elite penny stocks with strong financials
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com